Novus Acquisition & Development Corp. d/b/a Novus Cannabis MedPlan (OTC: NDEV) has reported its Q1 2026 financial highlights, positioning itself within the evolving landscape of federal medical cannabis rescheduling. The company, which operates as a specialized cannabis and traditional health insurance carrier, notes fiscal stability and operational efficiency as the shift to Schedule III begins to alleviate the impact of 280E tax provisions, according to a report by InsuranceNewsNet.
Novus maintains its market position through its wholly owned subsidiary, WCIG Insurance Service, Inc., by integrating medicinal cannabis coverage into a conventional insurance plan framework. This strategy employs a reimbursement model designed to incorporate cannabis-related benefits into the broader medical ecosystem, while also establishing a new revenue channel for cannabis industry verticals. This development builds on earlier coverage of the federal rescheduling of medical cannabis.
Operational Readiness and Market Positioning
Since 2015, Novus has developed a nationwide health carrier framework and a national network within the cannabis industry. Its portfolio of insurance benefit plans, including supplemental, discount, and guaranteed coverage options, is structured to integrate with various external health insurance carriers and wholesalers.
The company’s distribution network has expanded to over 5,000 agents and brokerage firms, providing access to more than 15,000 individual agents. This reach extends to millions of prospective policyholders across group, individual, and Medicare sectors, driven by the regulatory landscape changes.
The Role of Cannabis Insurance Coverage
Novus emphasizes its approach to transitioning cannabis from a retail commodity to a benefits-eligible item. By focusing on insurance receivables rather than depreciating assets, NDEV aims to offer a high-margin, non-cyclical entry point into alternative medicine. The company highlights its “Non-Touch” Advantage, indicating that its operations are not directly involved in cultivation, processing, or sales of the plant, thus reducing exposure to federal legislative delays.
A proprietary Rx platform is reported to facilitate a 15% to 17% reduction in effective tax burden for medicinal users. Furthermore, a unique reimbursement methodology is stated to deliver savings of 30% to 40% for policyholders, simultaneously creating a revenue channel for cannabis industry verticals to recover point-of-sale discounts.
Q1 2026 Financial Performance
Novus reported specific financial indicators for the first quarter of 2026 compared to the first quarter of 2025:
- EBITDA: Increased by 14.7%.
- Total Revenues: Saw a 9.8% uptick.
- Liquidity: Cash and Cash Equivalents grew by 10.7%.
- Capital Structure: The company maintains a simple debt-to-equity structure with no outstanding convertible notes.
Frank Labrozzi, CEO of Novus, stated that the move to Schedule III is narrowing the “Affordability Gap” in cannabis medicine, and that Novus has spent a decade building the necessary infrastructure for this market shift.
Strategic Infrastructure and Future Outlook
Novus positions itself as an “Infrastructure Play” for 2026, citing several strategic advantages:
- Tax Neutralization: The company aims to help policyholders save as the Schedule III transition eases 280E tax pressure.
- Scalable Overhead Efficiency: By owning receivables (insurance policies) rather than depreciating hard assets, Novus states its Embedded Value (EV) remains high.
- Barrier to Entry: The Novus carrier model generates cost reductions for patients, fostering an ecosystem that serves as a barrier for smaller competitors.
- New Revenue Stream Positioning: Novus is prepared to support federal research projects and Medicare pilot programs as a “Medicare & Research Pilot Gateway.”
- Data Advantage: Maintaining a multi-brand network provides extensive, cross-variable analytics for integration into the national healthcare system.
The cannabis sector is transitioning from a localized retail industry into a component of the comprehensive healthcare framework. By early 2026, market expansion exceeded forecasts, with over 6 million Americans enrolled as medicinal cannabis patients. This patient base is projected to reach approximately 12 million as federal tax changes encourage consumers to pursue health insurance that includes cannabis insurance coverage.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
